PL371416A1 - Farmaceutyczne postacie dawkowania o kontrolowanym uwalnianiu inhibitora białka przenoszącego estercholesterylu - Google Patents
Farmaceutyczne postacie dawkowania o kontrolowanym uwalnianiu inhibitora białka przenoszącego estercholesteryluInfo
- Publication number
- PL371416A1 PL371416A1 PL03371416A PL37141603A PL371416A1 PL 371416 A1 PL371416 A1 PL 371416A1 PL 03371416 A PL03371416 A PL 03371416A PL 37141603 A PL37141603 A PL 37141603A PL 371416 A1 PL371416 A1 PL 371416A1
- Authority
- PL
- Poland
- Prior art keywords
- dosage forms
- controlled release
- pharmaceutical dosage
- release pharmaceutical
- transfer protein
- Prior art date
Links
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 title 1
- 238000013270 controlled release Methods 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35371902P | 2002-02-01 | 2002-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL371416A1 true PL371416A1 (pl) | 2005-06-13 |
Family
ID=27663244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03371416A PL371416A1 (pl) | 2002-02-01 | 2003-01-20 | Farmaceutyczne postacie dawkowania o kontrolowanym uwalnianiu inhibitora białka przenoszącego estercholesterylu |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20030198674A1 (pl) |
| EP (1) | EP1474144B1 (pl) |
| JP (1) | JP2005522424A (pl) |
| KR (1) | KR20040083493A (pl) |
| CN (1) | CN1625397A (pl) |
| AR (1) | AR038385A1 (pl) |
| AT (1) | ATE403432T1 (pl) |
| BR (1) | BR0307332A (pl) |
| CA (1) | CA2473991C (pl) |
| DE (1) | DE60322665D1 (pl) |
| ES (1) | ES2309294T3 (pl) |
| GT (1) | GT200300023A (pl) |
| HN (1) | HN2003000054A (pl) |
| IL (1) | IL162870A0 (pl) |
| MX (1) | MXPA04005647A (pl) |
| NO (1) | NO20043506L (pl) |
| PA (1) | PA8565101A1 (pl) |
| PE (1) | PE20030806A1 (pl) |
| PL (1) | PL371416A1 (pl) |
| RU (1) | RU2004123637A (pl) |
| TW (1) | TW200303204A (pl) |
| UY (1) | UY27643A1 (pl) |
| WO (1) | WO2003063868A1 (pl) |
| ZA (1) | ZA200404718B (pl) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100664822B1 (ko) | 2002-02-01 | 2007-01-04 | 화이자 프로덕츠 인코포레이티드 | 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법 |
| GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| US20040122048A1 (en) * | 2002-10-11 | 2004-06-24 | Wyeth Holdings Corporation | Stabilized pharmaceutical composition containing basic excipients |
| EP1961419B1 (en) * | 2002-12-20 | 2010-03-24 | Pfizer Products Inc. | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor |
| WO2004085996A2 (en) * | 2003-03-20 | 2004-10-07 | Albert Einstein College Of Medicine Of Yeshiva University | Biomarkers for longevity and disease and uses thereof |
| CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| PL1670768T3 (pl) | 2003-10-08 | 2010-01-29 | Lilly Co Eli | Związki i sposoby leczenia dyslipidemii |
| WO2005065656A2 (en) * | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers |
| EA200601785A1 (ru) | 2004-03-26 | 2007-02-27 | Эли Лилли Энд Компани | Соединения и способы лечения дислипидемии |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| MY139887A (en) | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| WO2006069162A1 (en) * | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| DK1848430T3 (da) | 2004-12-31 | 2017-11-06 | Dr Reddys Laboratories Ltd | Nye benzylamin-derivativer som cetp-inhibitors |
| US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| WO2006079921A2 (en) * | 2005-01-28 | 2006-08-03 | Pfizer Products Inc. | Drying of drug-containing particles |
| EP1845953A1 (en) * | 2005-02-03 | 2007-10-24 | Pfizer Products Incorporated | Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
| UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
| UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| AU2007212197B2 (en) * | 2006-02-09 | 2012-12-13 | Merck Sharp & Dohme Corp. | Polymer formulations of CETP inhibitors |
| GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| PT2043610E (pt) * | 2006-07-21 | 2015-10-22 | Bend Res Inc | Secagem de partículas contendo fármacos |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| WO2008065506A2 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein |
| US20100062073A1 (en) * | 2006-11-29 | 2010-03-11 | Ronald Arthur Beyerinck | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| CA2682752C (en) * | 2007-04-05 | 2015-07-07 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
| US8900629B2 (en) | 2007-04-05 | 2014-12-02 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
| MX2009010962A (es) | 2007-04-13 | 2009-12-16 | Kowa Co | Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo. |
| US8703204B2 (en) * | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
| CA2923102C (en) | 2007-08-13 | 2019-10-15 | Omeho Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| SMT202000093T1 (it) * | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
| CA2845284C (en) | 2011-08-18 | 2018-03-06 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors |
| JP6140168B2 (ja) | 2011-09-27 | 2017-05-31 | ドクター レディズ ラボラトリーズ リミテッド | アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体 |
| WO2014146093A2 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
| KR101610465B1 (ko) | 2014-04-11 | 2016-04-07 | 국립암센터 | 다목적용 의료 영상 표지자 및 이의 제조방법 |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
| CN104474553A (zh) * | 2014-11-26 | 2015-04-01 | 嘉应学院医学院 | 一种基于β-谷甾醇的药物缓释剂及其制备方法 |
| US12133911B2 (en) | 2015-06-09 | 2024-11-05 | Capsugel Belgium Nv | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| CN107098946B (zh) * | 2016-02-23 | 2021-01-29 | 中国药科大学 | Cetp抑制剂的合成与用途 |
| EP3990845B1 (en) | 2019-06-26 | 2024-04-17 | Carrier Corporation | Transportation refrigeration unit with adaptive defrost |
| AU2020349524B2 (en) | 2019-09-18 | 2026-05-07 | Bristol-Myers Squibb Company | Dosage forms for Tyk2 inhibitors |
| EP4213813A1 (en) * | 2020-09-18 | 2023-07-26 | Bristol-Myers Squibb Company | Dosage forms for tyk2 inhibitors comprising swellable cores |
| WO2024189127A1 (en) * | 2023-03-14 | 2024-09-19 | Prolevi Bio Ab | Compositions for sustained release of poorly soluble active ingredients |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US91643A (en) * | 1869-06-22 | Improvement in gang-plows | ||
| US28895A (en) * | 1860-06-26 | Machine for wetting paper | ||
| US18446A (en) * | 1857-10-20 | Improvement in steam-plows | ||
| US54038A (en) * | 1866-04-17 | Improvement in priming metallic cartridges | ||
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4247498A (en) | 1976-08-30 | 1981-01-27 | Akzona Incorporated | Methods for making microporous products |
| US4564488A (en) | 1978-07-31 | 1986-01-14 | Akzo Nv | Methods for the preparation of porous fibers and membranes |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4490431A (en) | 1982-11-03 | 1984-12-25 | Akzona Incorporated | 0.1 Micron rated polypropylene membrane and method for its preparation |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US5225192A (en) | 1988-10-17 | 1993-07-06 | Vectorpharma International S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| AU1537292A (en) | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| DE4316537A1 (de) | 1993-05-18 | 1994-11-24 | Basf Ag | Zubereitungen in Form fester Lösungen |
| DE4327063A1 (de) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften |
| US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US5880095A (en) * | 1994-11-12 | 1999-03-09 | Lg Chemical Ltd. | Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| SI9500173B (sl) | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
| US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US5686133A (en) | 1996-01-31 | 1997-11-11 | Port Systems, L.L.C. | Water soluble pharmaceutical coating and method for producing coated pharmaceuticals |
| US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
| US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| PT1115695E (pt) | 1998-09-25 | 2005-10-31 | Monsanto Co | (n+1) -alcanois 1-aminossubstituidos (r) -quirais halogenados uteis para inibir a actividade da proteina de transferencia de ester de colesterilo |
| US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| ATE404178T1 (de) * | 1999-02-10 | 2008-08-15 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter wirkstofffreisetzung |
| DZ3227A1 (fr) | 1999-12-23 | 2001-07-05 | Pfizer Prod Inc | Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees |
| AU783685B2 (en) * | 1999-12-23 | 2005-11-24 | Pfizer Products Inc. | Hydrogel-driven drug dosage form |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| JP4547148B2 (ja) * | 2001-06-22 | 2010-09-22 | ベンド・リサーチ・インコーポレーテッド | 非晶質薬剤の吸着物の医薬組成物 |
| JP4644397B2 (ja) * | 2001-09-05 | 2011-03-02 | 信越化学工業株式会社 | 難溶性薬物を含む医薬用固形製剤の製造方法 |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
-
2003
- 2003-01-20 PL PL03371416A patent/PL371416A1/pl not_active Application Discontinuation
- 2003-01-20 CA CA002473991A patent/CA2473991C/en not_active Expired - Fee Related
- 2003-01-20 IL IL16287003A patent/IL162870A0/xx unknown
- 2003-01-20 MX MXPA04005647A patent/MXPA04005647A/es unknown
- 2003-01-20 KR KR10-2004-7011853A patent/KR20040083493A/ko not_active Ceased
- 2003-01-20 JP JP2003563558A patent/JP2005522424A/ja active Pending
- 2003-01-20 CN CNA038030438A patent/CN1625397A/zh active Pending
- 2003-01-20 WO PCT/IB2003/000209 patent/WO2003063868A1/en not_active Ceased
- 2003-01-20 EP EP03700414A patent/EP1474144B1/en not_active Expired - Lifetime
- 2003-01-20 ES ES03700414T patent/ES2309294T3/es not_active Expired - Lifetime
- 2003-01-20 BR BR0307332-7A patent/BR0307332A/pt not_active IP Right Cessation
- 2003-01-20 DE DE60322665T patent/DE60322665D1/de not_active Expired - Fee Related
- 2003-01-20 AT AT03700414T patent/ATE403432T1/de not_active IP Right Cessation
- 2003-01-20 RU RU2004123637/15A patent/RU2004123637A/ru not_active Application Discontinuation
- 2003-01-23 US US10/349,600 patent/US20030198674A1/en not_active Abandoned
- 2003-01-29 PE PE2003000098A patent/PE20030806A1/es not_active Application Discontinuation
- 2003-01-30 TW TW092102281A patent/TW200303204A/zh unknown
- 2003-01-30 GT GT200300023A patent/GT200300023A/es unknown
- 2003-01-30 HN HN2003000054A patent/HN2003000054A/es unknown
- 2003-01-31 UY UY27643A patent/UY27643A1/es not_active Application Discontinuation
- 2003-01-31 AR ARP030100294A patent/AR038385A1/es unknown
- 2003-02-03 PA PA20038565101A patent/PA8565101A1/es unknown
-
2004
- 2004-06-14 ZA ZA200404718A patent/ZA200404718B/en unknown
- 2004-08-23 NO NO20043506A patent/NO20043506L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL162870A0 (en) | 2005-11-20 |
| PA8565101A1 (es) | 2003-11-12 |
| GT200300023A (es) | 2003-09-17 |
| PE20030806A1 (es) | 2003-09-19 |
| AR038385A1 (es) | 2005-01-12 |
| US20030198674A1 (en) | 2003-10-23 |
| BR0307332A (pt) | 2004-12-07 |
| ATE403432T1 (de) | 2008-08-15 |
| RU2004123637A (ru) | 2005-04-20 |
| UY27643A1 (es) | 2003-08-29 |
| CA2473991C (en) | 2009-09-15 |
| TW200303204A (en) | 2003-09-01 |
| WO2003063868A1 (en) | 2003-08-07 |
| MXPA04005647A (es) | 2005-03-23 |
| EP1474144B1 (en) | 2008-08-06 |
| EP1474144A1 (en) | 2004-11-10 |
| JP2005522424A (ja) | 2005-07-28 |
| CN1625397A (zh) | 2005-06-08 |
| ZA200404718B (en) | 2006-11-29 |
| KR20040083493A (ko) | 2004-10-02 |
| NO20043506L (no) | 2004-10-19 |
| DE60322665D1 (de) | 2008-09-18 |
| ES2309294T3 (es) | 2008-12-16 |
| CA2473991A1 (en) | 2003-08-07 |
| HN2003000054A (es) | 2003-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL162870A0 (en) | Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor | |
| AU2914202A (en) | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | |
| IL162843A0 (en) | Dosage form for oral administration of a pde4 inhibitor | |
| SI1485094T2 (sl) | Farmacevtska oblika za oralno dajanje etil estra 3((2-((4-(heksiloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzimidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline ali njegovih soli | |
| IL172875A0 (en) | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors | |
| IL198996A (en) | Use of a tyrosine kinase inhibitor for its preparation as a medicinal preparation | |
| IL158765A0 (en) | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | |
| EP1479666A4 (en) | ESTER CONNECTION AND THEIR MEDICAL USE | |
| AU2003264038A1 (en) | Combination pharmaceutical agents as inhibitors of hcv replication | |
| TWI319318B (en) | Modified release pharmaceutical formulation | |
| AU2003232398A1 (en) | Sustained release oral dosage forms of gabapentin | |
| HRP20050429A2 (en) | Dosage form of sodium ibuprofen | |
| AU2003223930A1 (en) | Pharmaceutical use of boronic acids and esters thereof | |
| AU2003276572A1 (en) | Pharmaceutical dosage forms of biguanide-sulfonylurea combinations | |
| IL165069A0 (en) | Immediate release pharmaceutical formulation | |
| AU2003225285A1 (en) | Oral dosage forms comprising fenofibrate | |
| AU2003260239A1 (en) | Solid dosage forms for rapid dissolution of poorly soluble drugs | |
| AU2003261067A1 (en) | Modified release ketoprofen dosage form | |
| AP2004003087A0 (en) | Oral dosage form for controlled drug release | |
| AU2003263480A8 (en) | Oral pharmaceutical compositions of fenofibrate having high bioavailability | |
| IL165125A0 (en) | Use of new etonogestrel esters | |
| PL363068A1 (pl) | Bioadhezyjne kompozycje farmaceutyczne oparte na niesteroidowych lekach przeciwzapalnych | |
| AU2003210386A1 (en) | Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases | |
| AU2003201731A1 (en) | Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors | |
| HK1083584A (en) | Pharmaceutical dosage forms of biguanide-sulfonylurea combinations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |